Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 2/20 | 0.33 |
| ▸ | PGK2 | P07205 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.30 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.30 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7870277 | 0.86 | PGK1 (0.44) | PGK1PGK2TSHRPTPN1MEN1 | |
| SCHEMBL6769521 | 0.82 | FDPS (0.42) | — | |
| SCHEMBL1556937 | 0.80 | PTPN1 (0.52) | PGK1PGK2TSHRPTPN1MEN1 | |
| Hydrogen Peroxide SCHEMBL8609891 | 0.80 | PTPN1 (0.52) | PGK1PGK2TSHRPTPN1MEN1 | |
| SCHEMBL5859053 | 0.80 | PTPN5 (0.46) | PGK1PGK2PTPN1PTPN2PTPN6 | |
| SCHEMBL8470305 | 0.78 | PGK1 (0.39) | PGK1PGK2TSHRPTPN1MEN1 | |
| SCHEMBL2382743 | 0.78 | TSHR (0.43) | PGK1PGK2TSHRALDH1A1GAA | |
| SCHEMBL23908217 | 0.77 | PGK1 (0.43) | PGK1PGK2TSHRPTPN1MEN1 | |
| SCHEMBL1354398 | 0.77 | MEN1 (0.42) | PGK1PGK2TSHRMEN1ALDH1A1 | |
| SCHEMBL17311345 | 0.77 | PGK1 (0.38) | PGK1PGK2PTPN1PTPN2PTPN6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6720344-B2 | BINDING TO NUCLEAR RECEPTOR PROTEINS; STIMULATING BMP-2 PROMOTER ACTIVITY | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2004-04-13 | — | — | US | disclosed |
| US-20030119791-A1 | Methods and compositions for stimulating osteoblast proliferation or treating malignant cell proliferation and methods for selecting osteoblast proliferation stimulants | KERWIN SEAN M (US) | 2003-06-26 | — | — | US | disclosed |
| EP-0912549-A4 | COMPOUNDS AND METHODS FOR PROVIDING PHARMACOLOGICALLY ACTIVE PREPARATIONS AND USES THEREOF | UNIV TEXAS (US) | 2002-01-02 | — | — | EP | disclosed |
| EP-0912549-A1 | COMPOUNDS AND METHODS FOR PROVIDING PHARMACOLOGICALLY ACTIVE PREPARATIONS AND USES THEREOF | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1999-05-06 | — | — | EP | disclosed |
| WO-1997048694-A1 | COMPOUNDS AND METHODS FOR PROVIDING PHARMACOLOGICALLY ACTIVE PREPARATIONS AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1997-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119791-A1 | Methods and compositions for stimulating osteoblast proliferation or treating malignant cell proliferation and methods for selecting osteoblast proliferation stimulants | MKI67, HGF, AREG | PGK1 1770/4885PGK2 2196/4885TSHR 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.